Mayne Kaitlin J, Hanlon Peter, Lees Jennifer S
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Glasgow Renal and Transplant Unit, NHS Greater Glasgow and Clyde, Glasgow, UK.
Diabetes Obes Metab. 2024 Nov;26 Suppl 6:43-54. doi: 10.1111/dom.15625. Epub 2024 May 3.
Chronic kidney disease (CKD) is a major global health problem, affecting about 9.5% of the population and 850 million people worldwide. In primary care, most CKD is caused by diabetes and/or hypertension, but a substantial proportion of cases may have alternative causes. During the early stages, CKD is asymptomatic, and many people are unaware that they are living with the disease. Despite the lack of symptoms, CKD is associated with elevated risks of cardiovascular disease, progressive kidney disease, kidney failure and premature mortality. Risk reduction strategies are effective and cost-effective but require early diagnosis through testing of the estimated glomerular filtration rate and albuminuria in high-risk populations. Once diagnosed, the treatment of CKD centres around lifestyle interventions, blood pressure and glycaemic control, and preventative treatments for cardiovascular disease and kidney disease progression. Most patients with CKD should be managed with statins, renin-angiotensin-aldosterone system inhibitors and sodium-glucose cotransporter-2 inhibitors. Additional treatment options to reduce cardiorenal risk are available in patients with diabetes, including glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists. The Kidney Failure Risk Equation is a new tool that can support the identification of patients at high risk of progressive kidney disease and kidney failure and can be used to guide referrals to nephrology. This review summarizes the latest guidance relevant to managing adults with, or at risk of, CKD and provides practical advice for managing patients with CKD in primary care.
慢性肾脏病(CKD)是一个重大的全球健康问题,影响着全球约9.5%的人口,即8.5亿人。在初级医疗保健中,大多数CKD由糖尿病和/或高血压引起,但相当一部分病例可能有其他病因。在疾病早期,CKD没有症状,许多人并未意识到自己患有这种疾病。尽管没有症状,但CKD与心血管疾病、进行性肾病、肾衰竭和过早死亡风险升高相关。风险降低策略有效且具有成本效益,但需要通过检测高危人群的估计肾小球滤过率和蛋白尿进行早期诊断。一旦确诊,CKD的治疗围绕生活方式干预、血压和血糖控制以及心血管疾病和肾病进展的预防性治疗展开。大多数CKD患者应使用他汀类药物、肾素-血管紧张素-醛固酮系统抑制剂和钠-葡萄糖协同转运蛋白2抑制剂进行管理。对于糖尿病患者,还有其他降低心肾风险的治疗选择,包括胰高血糖素样肽-1受体激动剂和非甾体类盐皮质激素受体拮抗剂。肾衰竭风险方程是一种新工具,可帮助识别有进行性肾病和肾衰竭高风险的患者,并可用于指导转诊至肾脏病科。本综述总结了与管理患有CKD或有CKD风险的成年人相关的最新指南,并为初级医疗保健中管理CKD患者提供实用建议。